|Articles|September 22, 2004
- Pharmaceutical Executive-09-01-2004
September Table of Contents
TOC
Advertisement
Articles in this issue
about 21 years ago
(Huge) Untapped Opportunityabout 21 years ago
Information Into Actionabout 21 years ago
Halting the Hypeabout 21 years ago
Spend Trends: A $20 Billion Bill and Plenty of Changeabout 21 years ago
September Table of Contentsabout 21 years ago
From the Mouths of Babesabout 21 years ago
Safe and Secureabout 21 years ago
Synta's Surpriseabout 21 years ago
The New Building Blocks for Blockbustersabout 21 years ago
Specialty Therapies Lose Special StatusNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Announces New Plausible Mechanism Pathway
2
Roundup: Ovid Therapeutics and Metagenomi Announce 2025 Third Quarter Results and Leadership Updates
3
Pfizer’s Proven Playbook: Buy, Partner, Scale, Spin-Off, Optimize
4
Pharmaceutical Executive Daily: Dr. Richard Pazdur Appointed as Director CDER
5
